ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0026

Silencing of WISP-2 Induces Inflammatory Mediators and Catabolic Factors in Cartilage

Clara Ruiz-Fernández1, María González-Rodríguez2, Vera Francisco3, Djedjiga Ait Eldjoudi2, Alfonso Cordero-Barreal2, Yousof Farrag2, Jesús Pino4, Miguel Ángel González-Gay5, Antonio Mera6, Francisca Lago2 and Oreste Gualillo7, 1Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Galicia, Spain, 2Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain, 3Institute of Health Research-INCLIVA, València, Spain, 4Santiago Clinic Hospital CHUS-Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 6Santiago University Clinical Hospital CHUS, Santiago de Compostela, Spain, 7Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain

Meeting: ACR Convergence 2022

Keywords: chondrocyte, Inflammation, Interleukins, Metalloproteinase, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Osteoarthritis and Joint Biology – Basic Science Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Wnt-1 inducible signaling pathway protein 2 (WISP-2/CCN5) is an adipokine that has been described as an important mediator of canonical Wnt activation in adipogenic precursor cells. In osteoarthritis (OA), the most common form of arthritis, chondrocytes exhibit aberrant and increased production of pro-inflammatory mediators and matrix-degrading enzymes such as IL-1β and MMP-13. Although recent evidence suggests a role for Wnt signaling in OA physiopathology, little is known about the involvement of WISP-2 in cartilage degradation. In this study, we investigate the role of WISP-2 in cartilage inflammation and catabolism modulation.

Methods: For loss of function experiments, we silenced WISP-2 with siRNA in human T/C-28a2 chondrocytes and OA human primary chondrocytes. We determined mRNA and protein expression levels of catabolic and pro-inflammatory markers by RT-qPCR and western blot. We also assessed the protein expression levels of relevant factors involved in WNT/b-catenin signaling pathway by western blot.

Results: We investigated the catabolic and pro-inflammatory effects of WISP-2 gene silencing on cartilage ECM breakdown mediators and several cytokines and chemokines. WISP-2 gene knockdown increased MMP-13, ADAMTS-5, IL-6, IL-8, and IL-1β expression levels in human T/C-28a2 chondrocytes or OA human primary chondrocytes. We also tested WISP-2 as an activator of canonical Wnt signaling. To investigate Wnt/β-catenin signaling activation we addressed GSK-3 phosphorylation in WISP-2-silenced T/C-28a2 chondrocytes. Upon WISP-2 silencing there is a significant decrease in GSK-3 phosphorylation, suggesting that the accumulation and translocation of β-catenin to the nucleus, and the expression of downstream target genes, are compromised.

Since IL-1β has been implicated in cartilage degradation, we determined the effect of WISP-2 silencing on IL-1β-stimulated T/C-28a2 or human primary OA chondrocytes. IL-1β induced mRNA expression of MMP-13, ADAMTS-5, IL-6, and IL-8, while WISP-2 knockdown further increased IL-1β-induced expression of those genes.

To investigate the involvement of Wnt/β-catenin signaling, we transfected T/C-28a2 cells or human primary OA chondrocytes with siWISP-2 and treated them with IL-1β in the presence or not of selective GSK-3 inhibitor BIO. Activation of canonical Wnt signaling by BIO significantly decreased the expression of MMP-13, as well as ADAMTS-5, IL-6, and IL-8. Moreover, BIO treatment blocked the IL-1β-induced expression of the catabolic markers. Blocking GSK-3 with BIO almost completely suppressed the IL-1β-mediated upregulation of MMP-13, ADAMTS-5, IL-6, and IL-8 in siWISP-2-transfected cells.

Conclusion: In conclusion, here we have shown for the first time that WISP-2 may have relevant roles in modulating the turnover of extracellular matrix in the cartilage and that its downregulation may detrimentally alter the inflammatory environment in OA cartilage. We also proved the participation of Wnt/β-catenin signaling pathway in these processes. Thus, targeting WISP-2 might represent a potential therapeutical approach for degenerative and/or inflammatory diseases of the musculoskeletal system, such as osteoarthritis.

Supporting image 1

Figure 1. Effect of WISP_2 siRNA knockdown on chondrocyte catabolism and in canonical Wnt/β-catenin signaling pathway.
A. Human T/C_28a2 chondrocytes were transfected with negative control (siC-, 10 nM) or siRNA against WISP_2 (siWISP_2, 10 nM) for 48 hours. Determination of human MMP_13 protein expression by western blot in human OA chondrocytes. GAPDH was used as a loading control. Densitometric analysis was also shown. B. Determination of phosphorylated GSK_3 protein expression by western blot in human OA chondrocytes transfected with negative control (siC-, 10 nM) or siRNA against WISP_2 (siWISP_2, 10 nM) for 48 h. GAPDH was used as a loading control. C. Chondrocytes were transfected with negative control (siC-, 10 nM) or siRNA against WISP_2 (siWISP_2, 10 nM) in the presence or not of IL_1β (0.5 ng/mL) for 24 h in combination with 1 μM BIO. Determination of human MMP_13 protein expression by western blot in human primary OA chondrocytes. GAPDH was used as a loading control. Densitometric analysis was also shown.
Values are the mean ± SEM of at least three independent experiments (*p < 0.05, **p < 0.01,***p < 0.001 vs. siC-)


Disclosures: C. Ruiz-Fernández, None; M. González-Rodríguez, None; V. Francisco, None; D. Ait Eldjoudi, None; A. Cordero-Barreal, None; Y. Farrag, None; J. Pino, None; M. González-Gay, AbbVie/Abbott, Merck/MSD, Janssen, Roche, AbbVie/Abbott, Roche, Sanofi, Eli Lilly, Celgene, Sobi, Merck/MSD; A. Mera, None; F. Lago, None; O. Gualillo, None.

To cite this abstract in AMA style:

Ruiz-Fernández C, González-Rodríguez M, Francisco V, Ait Eldjoudi D, Cordero-Barreal A, Farrag Y, Pino J, González-Gay M, Mera A, Lago F, Gualillo O. Silencing of WISP-2 Induces Inflammatory Mediators and Catabolic Factors in Cartilage [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/silencing-of-wisp-2-induces-inflammatory-mediators-and-catabolic-factors-in-cartilage/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/silencing-of-wisp-2-induces-inflammatory-mediators-and-catabolic-factors-in-cartilage/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology